Durvalumab Extends OS in NSCLC
- PMID: 30327351
- DOI: 10.1158/2159-8290.CD-NB2018-135
Durvalumab Extends OS in NSCLC
Abstract
New data from the phase III PACIFIC trial of durvalumab in patients with stage III non-small cell lung cancer show that the drug increases the odds of surviving for 24 months. The study also confirms that progression-free survival and time to death or distant metastasis are longer for patients treated with durvalumab than for patients who received a placebo.
©2018 American Association for Cancer Research.
Comment on
-
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
